Research Paper Volume 16, Issue 1 pp 402—430

Figure 6. The relationship between the ARL score and immune cell infiltration, immunotherapy response, and chemotherapy sensitivity. (A) Comparison of immune cell infiltration in low versus high ARL score groups. (B) Comparison of enrichment of immune-related pathways between low versus high ARL score groups. (C) Comparison of immune and stromal scores between low versus high ARL groups. (D) Comparison of tumor mutation burden between low versus high ARL groups. (E) Comparison of expression levels of selected checkpoints between low versus high ARL score groups. (F) Comparison of immunotherapy response of PD-1 and CTLA4 between low versus high ARL score groups based on the results of immunogenomic analyses from The Cancer Immunome Atlas. (G) Comparison of immunotherapy response of PD-1 and CTLA4 between low versus high ARL score groups based on TIDE score. (H) Correlation between IC₅₀ values of common chemotherapy drugs for breast cancer and ARL scores. Statistical significance symbols: ns, p ≥ 0.05; ^*p < 0.05; ^**p < 0.01; ^***p < 0.001.